Shots:

• Thermo Fisher acquires a manufacturing facility in Ireland from GSK for ~$100M cash to develop & commercialize APIs for multiple diseases including childhood cancer- depression and Parkinson's. The transaction is expected to close in H2’19 including regulatory approvals
• The focus of the acquisition is to expand Thermo Fischer’s APIs manufacturing capabilities. Under a multi-year supply agreement- Thermo Fisher will continue to develop APIs for GSK
• The manufacturing facility has 270m³ of reactor capacity- 10 production buildings- R&D pilot plant and a lab- supporting the development process- scale-up and physical characterization of APIs

Ref: Thermo Fisher | Image: GSK